|
 Nubeqa, when combined with standard therapy, reduced the risk of
dying during the trial period by 32.5% in a comparison to standard
therapy alone, the German company said in a statement on Thursday,
citing trial results.
Nubeqa, also known as darolutamide and jointly developed with
Finnish drugmaker Orion, is already approved in non-metastatic
prostate cancer that cannot be treated with standard hormone
therapy, and the new results point to a larger market opportunity if
regulators clear the wider use.
Bayer, which is paying billions to settle U.S. claims its Roundup
weedkiller caused cancer, needs to strengthen its drug development
pipeline as its two pharmaceutical best-sellers, stroke prevention
pill Xarelto and eye drug Eylea, face a decline in sales in a few
years.
[to top of second column] |
 Nubeqa is one of three Bayer
pharmaceuticals that the company expects to
generate more than $1 billion in peak annual
sales, known in the industry as blockbusters,
alongside kidney disease treatment finerenone
and menopausal symptoms relief elinzanetant.
The trial's overall success was announced in
December and detailed results were published in
The New England Journal of Medicine on Thursday.
(Editing by Miranda Murray)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
